9,887 Shares in Neurocrine Biosciences, Inc. $NBIX Bought by Fox Run Management L.L.C.

Fox Run Management L.L.C. bought a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 9,887 shares of the company’s stock, valued at approximately $1,388,000.

A number of other large investors have also recently added to or reduced their stakes in the company. Geneos Wealth Management Inc. boosted its position in shares of Neurocrine Biosciences by 143.6% during the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock worth $25,000 after buying an additional 135 shares during the period. Golden State Wealth Management LLC raised its position in Neurocrine Biosciences by 120.5% in the 3rd quarter. Golden State Wealth Management LLC now owns 183 shares of the company’s stock valued at $26,000 after buying an additional 100 shares during the last quarter. Eastern Bank acquired a new stake in Neurocrine Biosciences in the 3rd quarter valued at approximately $27,000. Quent Capital LLC bought a new stake in Neurocrine Biosciences in the 3rd quarter valued at approximately $32,000. Finally, MAI Capital Management boosted its position in Neurocrine Biosciences by 101.2% during the 2nd quarter. MAI Capital Management now owns 328 shares of the company’s stock worth $41,000 after acquiring an additional 165 shares during the last quarter. Institutional investors own 92.59% of the company’s stock.

Insider Transactions at Neurocrine Biosciences

In other Neurocrine Biosciences news, CEO Kyle Gano sold 36,400 shares of Neurocrine Biosciences stock in a transaction on Friday, January 16th. The shares were sold at an average price of $132.70, for a total transaction of $4,830,280.00. Following the completion of the transaction, the chief executive officer directly owned 140,407 shares of the company’s stock, valued at $18,632,008.90. The trade was a 20.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Leslie V. Norwalk sold 5,000 shares of the company’s stock in a transaction on Monday, December 15th. The shares were sold at an average price of $152.23, for a total transaction of $761,150.00. Following the completion of the transaction, the director owned 7,429 shares in the company, valued at approximately $1,130,916.67. This represents a 40.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 46,966 shares of company stock worth $6,474,616. 4.80% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

NBIX has been the topic of a number of recent research reports. Canaccord Genuity Group lifted their price objective on shares of Neurocrine Biosciences from $160.00 to $164.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Wells Fargo & Company decreased their target price on shares of Neurocrine Biosciences from $180.00 to $175.00 and set an “overweight” rating for the company in a research report on Friday, February 13th. Morgan Stanley reissued an “equal weight” rating and set a $175.00 price target (up from $173.00) on shares of Neurocrine Biosciences in a research report on Thursday, January 8th. JPMorgan Chase & Co. decreased their price objective on Neurocrine Biosciences from $177.00 to $176.00 and set an “overweight” rating for the company in a report on Tuesday, February 17th. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Neurocrine Biosciences in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Neurocrine Biosciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $175.05.

Neurocrine Biosciences Price Performance

Neurocrine Biosciences stock opened at $131.15 on Thursday. The company’s 50-day moving average is $136.38 and its 200-day moving average is $140.44. The firm has a market capitalization of $13.16 billion, a PE ratio of 28.14, a P/E/G ratio of 0.68 and a beta of 0.31. Neurocrine Biosciences, Inc. has a fifty-two week low of $84.23 and a fifty-two week high of $160.18.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Wednesday, February 11th. The company reported $1.88 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.36 by ($0.48). The firm had revenue of $805.50 million during the quarter, compared to analyst estimates of $804.21 million. Neurocrine Biosciences had a net margin of 16.73% and a return on equity of 16.48%. The company’s revenue for the quarter was up 28.3% on a year-over-year basis. During the same quarter last year, the business posted $1.69 earnings per share. As a group, analysts expect that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current year.

Neurocrine Biosciences Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.